Our Members


Paratek Pharmaceuticals, Inc.

About Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

How we share on the AMR Register To obtain Paratek’s AMR surveillance data for analysis, researchers should use the AMR Register platform to submit a request. The anonymized data will then be made available to the researcher to download. Data for ongoing surveillance programs will be updated annually.
Programs Listed for Sharing Paratek’s AMR surveillance data available on the AMR Register:
• KEYSTONE – Omadacycline
What information will be provided Where available, the following data and information is provided for each dataset:

🗹 Raw dataset. This is the dataset containing the anonymized isolate level data collected during the study. The dataset can be downloaded.

🗹 Program description. Information about how the data were collected are provided on the program pages.

🗹 Links to Publications. Links to journal publications based on the data collected are provided on the program pages.

Questions or enquiries Please send any questions or enquiries to amr@vivli.org
Paratek’s Register or Website http://paratek-keystone.com